Physician profile

Debra E Towery

Family · Asheville, NC

NPI 1184026130

$1,832.10

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$15.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

Show all 25 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $36.99 2021
Amarin Pharma, INC. $36.15 2021
Pfizer INC. $33.88 2021
Takeda Pharmaceuticals U.S.A., INC. $31.80 2021
Sanofi-Aventis U.S. LLC $19.84 2021
Boston Scientific Corporation $17.02 2021
Dexcom, INC. $16.97 2021
Lilly USA, LLC $16.70 2021
E.R. Squibb & Sons, L.L.C. $13.66 2021
Eisai INC. $12.93 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Debra E Towery

$1,832.10

in general payments reported 2019-2025

Years
2021-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/11203682/debra-e-towery

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.